3 Specialty Pharma Maker, Global Generics Leader and Branded Medicines Company Stocks With a Strong Future Roadmap: JB Chemicals and Pharmaceuticals, Dr. Reddy’s Laboratories and Alkem Laboratories
- October 26, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
JB Chemicals and Pharmaceuticals, Dr. Reddy’s Laboratories and Alkem Laboratories: ROE of 11.1% to 17.1% and FY22 to FY26 revenue CAGR of 9.1% to 14.3%. Prices as of 23 Oct 2026.
Quick Answer
The three branded pharma and specialty generics stocks to watch are JB Chemicals and Pharmaceuticals, Dr. Reddy’s Laboratories and Alkem Laboratories. Their return on equity ranges from 11.1% to 17.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.1% to 14.3%. JB Chemicals and Pharmaceuticals leads on both return on equity at 17.1% and revenue growth at 14.3% a year. Prices are based on the 23 October 2026 close, and this article is educational, not investment advice.
Branded pharma and specialty generics stocks let investors follow companies that serve a growing part of the Indian economy. JB Chemicals and Pharmaceuticals, Dr. Reddy’s Laboratories and Alkem Laboratories cover a specialty pharma maker, a global generics leader and a branded medicines company.
This list covers three branded pharma and specialty generics stocks with complete current figures: JB Chemicals and Pharmaceuticals, Dr. Reddy’s Laboratories and Alkem Laboratories. Every figure comes from the latest reported financials and the 23 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Branded Pharma and Specialty Generics Stocks?
Branded pharma and specialty generics stocks are listed drug makers that sell branded medicines in India and generics abroad. Their earnings depend on new launches, chronic therapy growth, regulatory approvals and pricing.
Branded Pharma and Specialty Generics Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| JB Chemicals and Pharmaceuticals | 2,408.9 | 38,731 | 54.6 | 35.8 | 17.1 | 0.00 |
| Dr. Reddy’s Laboratories | 1,229.5 | 103,667 | 32.6 | 36.0 | 11.1 | 0.20 |
| Alkem Laboratories | 4,947 | 59,723 | 27.1 | 36.0 | 16.7 | 0.15 |
On valuation, Dr. Reddy’s Laboratories and Alkem Laboratories trade at a P/E below the industry P/E, while JB Chemicals and Pharmaceuticals trades above it, which reflects the growth the market already expects. Readers comparing branded pharma and specialty generics stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Branded Pharma and Specialty Generics Stocks Have a Strong Roadmap in India?
Branded pharma and specialty generics stocks have a strong roadmap in India because rising healthcare access, a growing chronic disease burden and a trusted export base keep lifting demand for medicines.
- Chronic therapies. Long-term treatments give repeat demand.
- Export generics. Overseas approvals widen markets.
- Domestic brands. Doctors prescribe trusted medicines.
Why JB Chemicals and Pharmaceuticals Features Among These Branded Pharma and Specialty Generics Stocks
Among the branded pharma and specialty generics stocks on this list, JB Chemicals and Pharmaceuticals is a Mumbai-based pharmaceutical company that sells branded formulations in India in cardiac, gastro-intestinal and other therapies, exports to several markets and runs a contract development and manufacturing business.
The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P/E of 54.6, above the industry P/E of 35.8.
Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%.
Roadmap: The company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.
What to watch: Monitor the growth of key domestic brands and the order flow in contract manufacturing.
Why Dr. Reddy’s Laboratories Features Among These Branded Pharma and Specialty Generics Stocks
Among the medicine maker business shares on this list, Dr. Reddy’s Laboratories is a Hyderabad-based pharmaceutical company that makes generics, active ingredients and branded products for India and global markets, with a large presence in North America and Europe.
Revenue rose from Rs 22,030 crore in FY22 to Rs 35,059 crore in FY26, a compound annual growth rate of 12.3%. Net profit grew from Rs 2,182 crore in FY22 to Rs 4,158 crore in FY26, which works out to a compound annual growth rate of 17.5%.
The company has a return on equity of 11.1%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 103,667 crore. The stock trades at a P/E of 32.6, below the industry P/E of 36.0.
Roadmap: The company is widening its product pipeline with complex generics, biosimilars and consumer health, while its domestic business adds steady growth. Investment in research supports a stream of new launches.
What to watch: Monitor launches of complex generics and the progress of biosimilar programmes.
Why Alkem Laboratories Features Among These Branded Pharma and Specialty Generics Stocks
Among the three companies on this list, Alkem Laboratories is a Mumbai-based pharmaceutical company with a leading domestic franchise in anti-infectives, gastro-intestinal, pain and vitamins, along with exports of generics and a contract manufacturing and active ingredient business.
In the June 2026 quarter, revenue grew 11.0% year on year to Rs 3,893 crore. Revenue rose from Rs 10,797 crore in FY22 to Rs 15,296 crore in FY26, a compound annual growth rate of 9.1%.
Net profit grew from Rs 1,680 crore in FY22 to Rs 2,353 crore in FY26, which works out to a compound annual growth rate of 8.8%. The company has a return on equity of 16.7%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 59,723 crore. The stock trades at a P/E of 27.1, below the industry P/E of 36.0.
Roadmap: Alkem’s strong domestic brands and wide medical representative network support steady growth, while its international business adds regulated market exposure. The company is also building its chronic and specialty portfolio and its biosimilars pipeline.
What to watch: Check the growth in chronic therapies in India and the contribution from the international and contract manufacturing businesses.
JB Chemicals and Pharmaceuticals vs Dr. Reddy’s Laboratories vs Alkem Laboratories on Key Financials
The table below sets the three branded pharma and specialty generics stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| JB Chemicals and Pharmaceuticals | 2,463 | 4,208 | 14.3% | 709 | 16.9% |
| Dr. Reddy’s Laboratories | 22,030 | 35,059 | 12.3% | 4,158 | 11.9% |
| Alkem Laboratories | 10,797 | 15,296 | 9.1% | 2,353 | 15.4% |
JB Chemicals and Pharmaceuticals posts the highest return on equity in this group at 17.1%. Dr. Reddy’s Laboratories has the largest FY26 revenue at Rs 35,059 crore, and JB Chemicals and Pharmaceuticals shows the fastest revenue growth with a 14.3% compound annual rate. A useful habit with branded pharma and specialty generics stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Branded Pharma and Specialty Generics Stocks
Every theme carries risks that deserve a check before any decision. For these branded pharma and specialty generics stocks, the main points are:
- Regulatory checks. Plant inspections can affect approvals.
- Price pressure. Generic prices abroad can fall.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter branded pharma and specialty generics stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Branded Pharma and Specialty Generics Stocks
Branded pharma and specialty generics stocks reward investors who follow demand trends, order books and margins together. JB Chemicals and Pharmaceuticals, Dr. Reddy’s Laboratories and Alkem Laboratories each have a clear plan to widen their reach. Based on the 23 October 2026 close, JB Chemicals and Pharmaceuticals trades at Rs 2,408.9, Dr. Reddy’s Laboratories at Rs 1,229.5 and Alkem Laboratories at Rs 4,947.
Download the Univest iOS App or Univest Android App to track branded pharma and specialty generics stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are branded pharma and specialty generics stocks?
Ans. Branded pharma and specialty generics stocks are listed drug makers that sell branded medicines in India and generics abroad. Their earnings depend on new launches, chronic therapy growth, regulatory approvals and pricing. This list looks at three of them, JB Chemicals and Pharmaceuticals, Dr. Reddy’s Laboratories and Alkem Laboratories, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.
Which branded pharma and specialty generics stocks are covered in this list?
Ans. This list covers JB Chemicals and Pharmaceuticals, Dr. Reddy’s Laboratories and Alkem Laboratories. Based on the 23 October 2026 close, JB Chemicals and Pharmaceuticals traded at Rs 2,408.9, Dr. Reddy’s Laboratories at Rs 1,229.5 and Alkem Laboratories at Rs 4,947. Their return on equity ranges from 11.1% to 17.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.1% to 14.3%.
Why do branded pharma and specialty generics stocks have a strong future roadmap in India?
Ans. Branded pharma and specialty generics stocks have a strong roadmap in India because rising healthcare access, a growing chronic disease burden and a trusted export base keep lifting demand for medicines. The main drivers are as follows. Chronic therapies. Long-term treatments give repeat demand. Export generics. Overseas approvals widen markets. Domestic brands. Doctors prescribe trusted medicines. Together these factors give the companies on this list a visible path for growth over the coming years.
How has JB Chemicals and Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%. The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P/E of 54.6, above the industry P/E of 35.8. Looking ahead, the company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.
How has Dr. Reddy’s Laboratories performed financially?
Ans. Revenue rose from Rs 22,030 crore in FY22 to Rs 35,059 crore in FY26, a compound annual growth rate of 12.3%. Net profit grew from Rs 2,182 crore in FY22 to Rs 4,158 crore in FY26, which works out to a compound annual growth rate of 17.5%. The company has a return on equity of 11.1%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 103,667 crore. The stock trades at a P/E of 32.6, below the industry P/E of 36.0. Looking ahead, the company is widening its product pipeline with complex generics, biosimilars and consumer health, while its domestic business adds steady growth. Investment in research supports a stream of new launches.
How has Alkem Laboratories performed financially?
Ans. Revenue rose from Rs 10,797 crore in FY22 to Rs 15,296 crore in FY26, a compound annual growth rate of 9.1%. Net profit grew from Rs 1,680 crore in FY22 to Rs 2,353 crore in FY26, which works out to a compound annual growth rate of 8.8%. In the June 2026 quarter, revenue grew 11.0% year on year to Rs 3,893 crore. The company has a return on equity of 16.7%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 59,723 crore. The stock trades at a P/E of 27.1, below the industry P/E of 36.0. Looking ahead, alkem’s strong domestic brands and wide medical representative network support steady growth, while its international business adds regulated market exposure. The company is also building its chronic and specialty portfolio and its biosimilars pipeline.
What risks should investors check before buying branded pharma and specialty generics stocks?
Ans. Investors should check a few risks before buying branded pharma and specialty generics stocks. Regulatory checks. Plant inspections can affect approvals. Price pressure. Generic prices abroad can fall. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of branded pharma and specialty generics stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
